FPI-2265 is being explored in patients with metastatic castration-resistant prostate cancer in the ongoing phase 2 TATCIST trial; Results from this study are expected to be released Q1 of 2024. The ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at the American Urological Association (AUA) 2023 Annual Meeting validate the real-world ...
Water ablation therapy for BPH was safe and effective in real-world patients with prostate gland volumes of 80 mL or larger, even those exceeding 150 mL. Rezūm water vapor therapy is a safe and ...
In a recent large prospective study, vasectomy was associated with modestly higher risk of prostate cancer, especially high-grade and lethal prostate cancer. However, evidence from prospective studies ...
Advaxis expects to announce the next steps for ADXS-PSA by 1st half of 2020, being used to treat patients with prostate cancer in combination with Keytruda which is partnered with Merck. ADXS-503 ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback